Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.75 |
| ▸ | ABL2 | P42684 | 1/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.69 |
| ▸ | BRAF | P15056 | 7/20 | 0.66 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.64 |
| ▸ | BCR | P11274 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 3/20 | 0.62 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611057 | 0.94 | ABL1 (0.67) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL10265418 | 0.94 | ABL1 (0.66) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL9610979 | 0.93 | ABL1 (0.69) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL9611007 | 0.92 | ABL1 (0.64) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL10268800 | 0.92 | ABL1 (0.64) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL15871944 | 0.92 | ABL1 (0.64) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL9610971 | 0.91 | ABL1 (0.62) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL9610939 | 0.90 | ABL1 (0.76) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL9610992 | 0.88 | ABL1 (0.64) | ABL1ABL2MAPK14BRAFEGFR | |
| SCHEMBL9610986 | 0.88 | DDR1 (0.64) | ABL1ABL2MAPK14BCRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278971-B2 | Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012139027-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885ABL2 231/4885MAPK14 199/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | ABL1 4036/4885ABL2 3737/4885MAPK14 2888/4885 |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885ABL2 1006/4885MAPK14 4516/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885ABL2 1006/4885MAPK14 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.